Inogen Inc. Files 8-K with Financial Statements

TL;DR

Inogen filed an 8-K with financial statements on Dec 30, 2024.

AI Summary

On December 30, 2024, Inogen Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial performance. No specific material events or dollar amounts were detailed in the provided excerpt.

Why It Matters

This filing indicates Inogen Inc. is providing updated financial information, which could impact investor understanding of the company's current financial health and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

• Inogen Inc. (company) — Registrant
• December 30, 2024 (date) — Date of earliest event reported
• 859 Ward Drive, Goleta, California 93111 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value INGN The Nasdaq Stock Mar
• $13 million — the Company became obligated to make a $13 million cash earnout milestone payment (the "Ph

Filing Documents

• ingn-20241230.htm (8-K) — 43KB
• ingn-ex99_1.htm (EX-99.1) — 15KB
• img132417817_0.jpg (GRAPHIC) — 3KB
• 0000950170-24-140955.txt ( ) — 173KB
• ingn-20241230.xsd (EX-101.SCH) — 23KB
• ingn-20241230_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 30, 2024, Inogen, Inc. (the "Company") issued a press release announcing U.S. Food and Drug Administration ("FDA") 510(k) clearance of its Simeox 200 device intended to promote airway clearance and to improve bronchial drainage. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On December 30, 2024, the Company announced FDA 510(k) clearance of its Simeox 200 device intended to promote airway clearance and to improve bronchial drainage. Upon FDA 510(k) clearance of the Simeox 200 device, the Company became obligated to make a $13 million cash earnout milestone payment (the "Physio-Assist Milestone Payment") pursuant to the Share Purchase Agreement, dated July 10, 2023, by and among the Company and Mr. Adrien Mithalal, Mr. Jean-Sbastien Lantz, Mrs. Anne Reiser, CAAP Creation, Societe De Capital Risque Provencale Et Corse, Region Sud Investissement, Mrieux Participations 2, Relyens Innovation Sant and certain holders of exercisable securities identified therein (collectively, the "Sellers"). The Physio-Assist Milestone Payment must be made to the Sellers no later than ten business days following the date of the FDA 510(k) clearance .

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated December 30, 2024. 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INOGEN, INC. Date: December 30, 2024 By: /s/ Michael Bourque Michael Bourque Executive Vice President Chief Financial Officer Treasurer (Principal Accounting and Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR